Acadia Pharmaceuticals Inc., of San Diego, presented data at the International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, from its Phase III program testing pimavanserin in Parkinson's disease psychosis (PDP), including data from the pivotal -020 study and related -015 open-label safety extension trial...Mei Pharma Inc., of San Diego, said the first patients were dosed in a Phase II trial of its lead candidate, HDAC inhibitor Pracinostat, in combination with Vidaza

Santarus Inc., of San Diego, and Pharming Group, of Leiden, the Netherlands, said the FDA accepted for filing the biologics license application (BLA) for Ruconest (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema

Ambrx Inc., of San Diego, and Zhejiang Medicine Co

is that Zytiga will be coming off patent at just about the time we would expect, if all goes well, ARN-509 would be launched," said Paul Cleveland, chief financial officer for San Diego-based Aragon, a company with 40 employees that was founded less than four years ago

The new cash is expected to let San Diego-based Mast reach top-line data, said Brandi Roberts, chief financial officer, although it "probably won't get us through filing the new drug application and getting ready for commercialization...Earlier this month, Hemaquest Pharmaceuticals Inc., of San Diego, completed enrollment in a randomized, double-blind, placebo-controlled Phase IIb study of HQK-1001 , a small-chain fatty acid derivative, given orally twice per day

Filing its S-1 as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, the San Diego-based firm is seeking to raise up to $69 million to continue the clinical development of emricasan, a pan-caspase inhibitor

32 subjects completed the study, with no serious adverse events, dose-limiting safety findings or tolerability issues leading to withdrawal 5/8/13 Eleven Biotherapeutics Inc. (Cambridge, Mass.) EBI-005 An Interleukin-1 signaling inhibitor Dry eye disease Phase Ia data demonstrated it was safe and well tolerated 5/9/13 La Jolla Pharmaceutical Co. (San Diego) GCS-100 Carbohydrate molecule Chronic kidney disease Treated the last patient in the Phase I portion of the Phase I/II trial

Building on the incubator it established in San Diego, J&J has established a second incubator in the San Francisco Bay Area through an agreement with California Institute for Quantitative Biosciences (QB3) to rent space in the University of California sponsored incubator

San Diego) and Baxter International Inc. (Deerfield, Ill.) HyQvia Solution for subcutaneous use Primary and secondary immunodeficiencies European Commission granted marketing authorization in all European Union member states 5/22/13 Norgine BV (Amsterdam, the Netherlands) Xifaxan 550 mg

San Diego) Asonep A humanized antibody designed to neutralize sphingosine-1-phosphate Renal cell carcinoma Began dosing in a Phase IIa trial 5/24/13 Macrogenics Inc. (Rockville, Md.) Margetuximab Next-generation anti-HER2 monoclonal antibody Metastatic breast cancer First patient was dosed in a Phase II study at six U.S...the median progression-free survival time was 5.6 months 5/29/13 Syndax Pharmaceuticals Inc. (Waltham, Mass.) Entinostat HDAC inhibitor Estrogen receptor-positive breast cancer

Takeda California Inc., of San Diego, a subsidiary of Takeda Pharmaceutical Co

Madera Biosciences Inc., of San Diego, said it was awarded follow-on funding of $298,500 from the Alzheimer's Drug Discovery Foundation to further develop the firm's small-molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease

SAN DIEGO – At a Calbio session, Cambell Alliance, the business consulting segment of Inventiv Health Inc., presented its survey of business development professionals...We don't spend time arguing about forecasts," said Michael D. Step, senior vice president of corporate development at Santarus Inc., of San Diego

Trius Therapeutics Inc., of San Diego, published results of clinical and animal studies showing that its antibiotic TR-701 does not interact with monamine oxidase, meaning that if approved it could potentially be taken with antidepressants whose use is limited with agents that inhibit MAO

San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

company, Otonomy Inc., of San Diego, raised $48.5 million in two funding rounds in 2010

Biotie Therapies Corp., of Turku, Finland, obtained an exclusive option to acquire Neurelis Inc., of San Diego

Oncosec Medical Inc., of San Diego, signed a sponsored research agreement with Old Dominion University and the Frank Reidy Research Center for Bioelectrics

Trius Therapeutics Inc., of San Diego, named Matthew Onaitis general counsel and secretary